








key: cord-265322-3854ddb9
authors: Vavougios, George D.
title: A data-driven hypothesis on the epigenetic dysregulation of host metabolism by SARS coronaviral infection: potential implications for the SARS-CoV-2 modus operandi
date: 2020-04-23
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.109759
sha: 
doc_id: 265322
cord_uid: 3854ddb9

COVID-19, the disease caused by the novel SARS-CoV-2, a betacoronavirus structurally similar to SARS-CoV. Based on both structural and syndromic similarities with SARS-CoV, a hypothesis is formed on SARS-CoV-2 potential to affect the host’s metabolism as part of its lifecycle. This hypothesis is evaluated by (a) exploratory analysis of SARS-CoV / human transcriptomic interaction data and gene set enrichment analysis (b) a confirmatory, focused review of the literature based on the findings by (a). A STRING Viruses (available search for human – SARS-CoV (NCBI taxonomy Id: 9606 vs. NCBI taxonomy Id: 694009) genomic interactions reveals ten human proteins, interacting with SARS-CoV: SGTA, FGL2, SPECC1, STAT3, PHB, BCL2L1, PPP1CA, CAV1, JUN, XPO1. Gene set enrichment analyses (GSEA) with STRING on this network revealed their role as a putative protein – protein interaction network (PPI; Enrichment p-value=0.0296) mediating, viral parasitism, interleukin as well as insulin signaling, diabetes and triglyceride catabolism. In the literature, SARS-CoV has been known to cause de novo diabetes by ACE2-dependent uptake on pancreatic isle cells, and furthermore dysregulate lipid autophagy in favor of the viral lifecycle. Conversely, currently there are only non-causative, observational evidence of worse outcomes for COVID-19 patients with comorbid diabetes or hyperglycemia. No study has reported on the lipid profiles of COVID-19 patients; however, lipid-targeting molecules have been proposed as agents against SARS-CoV-2. Future studies, reporting on lipid and glucose metabolism of COVID-19 patients could help elucidate the disease’s seculae and aid drug design.

. COVID-19 is caused by the novel SARS-CoV-2, a betacoronavirus structurally similar (approximately 79%) to SARS-CoV (2) . In a recent study by Hoffmann et al. (3) , the similarities between the SARS viruses extend to ACE2 dependent host cell entry. At present, SARS-CoV-2 has shown significant similarities with SARS-CoV, both in clinical characteristics and exploited host intracellular functions (5) . Due to these commonalities, SARS-CoV remains an attractive substitute for the yet to be determined specifics of the SARS-CoV-2 / Human protein interaction (6) and its consequences.

Among the first studies to report clinical data on COVID19 was a recent publication by Yang and colleagues (6) . Their study provided the foundation for a hypothesis put forth by Fang and colleagues indicating that diabetic and hypertensive patients exposed to ACE2 inhibitors may be at an increased risk of more severe COVID-19 (7) . 

Meta-analyses on SARS cohorts have indicated that both a history of diabetes and hyperglycemia were independent factors of worse outcomes including more severe respiratory symptoms and death, regardless of medication (9) . In another study, SARS-CoV was shown to cause diabetes by ACE2-dependent infection of pancreatic isle cells (10) . Interestingly, the significantly enriched "cAMP signaling" pathway is an indirect link between diabetes and ACE2 signaling, based on experimental evidence associating cAMP levels and ACE2 activity in diabetic patients (11) (False Discovery Rate (FDR) <0.05); Table 1 . Following entry to host cells, lipid metabolism is a subsequent important target of single strand RNA viruses, critical for the formation of the viral envelope in subsequent lifecycles (12) . Autophagy mediated triglyceride and lipid droplet catabolism is one such mechanism, as identified in DENV infection (13) . Hijacking the host cells' lipid metabolism has been shown to be a critical step in establishing HCoV-22E and MERS -coronavirus latency (14) . In SARS-CoV patients, alterations in lipid metabolism have been detected as far as 12 years after the initial infection (15) .

Evidence on COVID-19's interplay with diabetes is only recently emerging, and can currently only be considered within the context of epidemiological studies, determining diabetes mellitus (DM) as frequent comorbidity. Furthermore, DM has recently been characterized as a determinant of more severe respiratory syndrome, along with other comorbidities (16) . Aside from DM, novel hyperglycemia was recently associated with an increased with worse outcomes in COVID-19 patients, however this association was not independent of other predictors in the multivariate model (17) .

Epidemiological associations between COVID-19 and lipid metabolism are currently not possible, since even large scale cohorts do not report on relevant measurements (18) . On the experimental level, lipid metabolism on the cellular level has been proposed as a treatment target for COVID-19; specifically, both interactions between SARS-CoV's spike protein with lipid rich membrane compartments, as well as the epigenetic modulations in lipid metabolism were considered as the end-point targets for the development of small molecules, aiming to prevent SARS-CoV-2 infection (19) .

Barring actual proteomics SARS-CoV-2, SARS-CoV based in silico analyses of the SARS-CoV -Human interaction partially support the hypothesis of Fang and colleagues, insofar as to warrant further scrutiny on COVID19 patient's metabolic states and concomitant medication. While the approach presented here is inherently limited due to setting its basis on the SARS-CoV proteomic interactions, it nevertheless presents in silico and literature evidence supporting SARS-CoV-2 potential to affect human metabolism. Furthermore, as genes affected by SARS-CoV infection are significantly enriched for other infections, they may represent a common interface, targeted by viruses. Future studies should determine SARS-CoV-2 interaction and effect on the human transcriptome, further identifying drug targets using pharmacogenomic enrichment analyses.

The author confirms that there are no known conflicts of interest associated with this manuscript and there has been no financial support for this work that could have influenced its outcome.

SARS-CoV-2 and COVID-19: The most important research questions

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors

Host Lipids in Positive-Strand RNA Virus Genome Replication

Dengue virus-induced autophagy regulates lipid metabolism

Modulation of Lipid Droplet Metabolism-A Potential Target for Therapeutic Intervention in Infections

Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?

The author confirms that there are no known conflicts of interest associated with this manuscript and there has been no financial support for this work that could have influenced its outcome.

George Vavougios MD, PhD 20. 21.

